Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Microfluidic-based Point of Care is Now a Must-have for Diagnostic Companies

Published: Saturday, May 17, 2014
Last Updated: Saturday, May 17, 2014
Bookmark and Share
“Point of Care Testing 2014: Applications for Microfluidic Technologies” report from Yole Développement.

“Diagnostic companies confirm the adoption of microfluidic technologies for point of care testing”, announces Dr Benjamin Roussel, Activity Leader, Medical Technologies, from Yole Développement.

Indeed the point of care market’s contribution to in vitro diagnostic is poised to increase from 13% to 17% over the next five years, leading to a market of around $30B in 2019. Under this context, the French consulting company, Yole Développement releases its report, “Point of Care Testing 2014: Applications for Microfluidic Technologies”.

This technology and market study provides an in-depth analysis of microfluidic devices dedicated to point of care; including nearly 60 new technologies, commercialized or close to the market, Yole
Développement’s report also proposes an innovative market segmentation combined with market forecasts.

This analysis includes the following applications: emergency testing - home tests - doctor’s office screening - decentralized hospital tests - environmental testing - Forensic and military - third-world infections - agro-food.

“Different types of point of care tests are available on the market. Whereas simple lateral flow tests work perfectly without fluid management technology, microfluidics is necessary when test complexity increases”, explains Benjamin from Yole Développement. Indeed, microfluidics is an enabling technology allowing miniaturization and integration of laboratory protocols into portable devices.

Point of care testing based on microfluidic technology is expected to grow sharply, from $1.6B in 2013 to $5.6B in 2019, at a CAGR 2014 - 2019 of 23%. Major diagnostics companies (Alere, Abbott Point of Care, BD Diagnostics, Cepheid, Abaxis, etc.) have realized the potential of rapid molecular diagnostic testing. Indeed, several successful point of care products based on microfluidic technology have been launched in the past few years.

Access to microfluidic technologies for diagnostic companies often passes through acquisitions, as this reduces the technology development risk and increases reactivity. The most recent acquisition was that of IQuum by Roche for $275M in April 2014.

In its new report, Yole Développement describes how mergers and acquisitions will decrease in volume but increase in value. Based on a complete analysis of the last three years’ developments, the company has been able to draw effective conclusions.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Size Matters for Particles in Bloodstream
Research uncovers more information about how particles behave in the human bloodstream.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Analytical Science Breakthrough Could Lead To Medical Revolution
A breakthrough in analytical science s could allow pharmaceutical research to be faster and more precise.
Lab-on-a-Chip Detects Effects of Poison
A fast and efficient mixer has been developed for testing the effect of toxic substances faster by using a new lab-on-a-chip.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Puttng Cells Through Their Paces
An obstacle course for human lung cells could be the answer for better testing the effectiveness of potential new drugs.
Dolomite Bio’s Single Cell RNA-Seq System Enables High Speed Encapsulation
Dolomite Bio has developed the Single-Cell RNA-Seq System for efficient, high throughput single cell transcriptomics.
NASA's DNA Sequencing in Space is a Success
DNA has been sequenced in space for the first time ever for the Biomolecule Sequencer investigation, using the MinION sequencing device.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos